| 1 |
NCT03462459 |
Recruiting |
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection |
- Recurrent Clostridium Difficile Infection
- Clostridium Difficile Infection
|
- Drug: Vancomycin
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- Indiana University
- Medical College of Wisconsin
- Agency for Healthcare Research and Quality (AHRQ)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Recurrent Clostridium difficile infection (CDI)
- Gut microbiome composition
- Vancomycin-resistant enterococcus (VRE) colonization in patients receiving vancomycin vs. placebo
- Determine whether Clostridium difficile positivity on any stool sample is a predictor of CDI recurrence.
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03462459 |
2017-0927
1R01HS025713-01 |
|
May 21, 2018 |
December 31, 2021 |
December 31, 2021 |
March 12, 2018 |
June 20, 2018 |
|
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
|
| 2 |
NCT02692651 |
Recruiting |
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections |
- Clostridium Difficile Infection (CDI)
|
- Drug: Fidaxomicin
- Drug: Vancomycin
|
Interventional
|
Phase 4 |
- University of Michigan
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Cure: Resolution of diarrhea
- Recurrence of CDI
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT02692651 |
Merck Fidaxo |
|
May 1, 2017 |
January 2020 |
April 2020 |
February 26, 2016 |
May 3, 2018 |
|
- University of Michigan
Ann Arbor, Michigan, United States
|
|
| 3 |
NCT03595566 |
Not yet recruiting |
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Drug: ridinilazole
- Drug: vancomycin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sustained clinical response defined as clinical cure at the Assessment of Cure (AOC) visit and no recurrence of CDI within 30 days post end of treatment (EOT)
- Clinical cure at Assessment of Cure (AOC) visit
- Sustained clinical response over 60 days
- (and 2 more...)
|
680 |
All |
18 Years and older (Adult, Older Adult) |
NCT03595566 |
SMT19969/C005 |
Ri-CoDIFy 2 |
March 2019 |
March 2021 |
May 2021 |
July 23, 2018 |
July 23, 2018 |
|
|
|
| 4 |
NCT03595553 |
Not yet recruiting |
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Drug: ridinilazole
- Drug: vancomycin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sustained clinical response defined as clinical cure at the Assessment of Cure (AOC) visit and no recurrence of CDI within 30 days post end of treatment (EOT)
- Clinical cure at Assessment of Cure (AOC) visit
- Sustained clinical response over 60 days
- (and 3 more...)
|
680 |
All |
18 Years and older (Adult, Older Adult) |
NCT03595553 |
SMT19969/C004 |
Ri-CoDIFy 1 |
March 2019 |
March 2021 |
May 2021 |
July 23, 2018 |
July 23, 2018 |
|
|
|
| 5 |
NCT02996487 |
Recruiting |
Screening to Prophylax Against Clostridium Difficile Infection - |
- Clostridium Difficile Infection
|
- Drug: Vancomycin
- Other: Placebo
|
Interventional
|
Phase 4 |
- William Beaumont Hospitals
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- The incidence of CDI in inpatients receiving vancomycin prophylaxis vs. placebo who are on high-risk antibiotics and are colonized with toxigenic C. difficile.
- The severity of CDI in patients receiving vancomycin prophylaxis vs. placebo.
- The outcome of CDI in patients receiving vancomycin prophylaxis vs. placebo.
- (and 2 more...)
|
2500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02996487 |
2016-254 |
StoP CDI |
December 2016 |
September 2020 |
September 2021 |
December 19, 2016 |
September 28, 2018 |
|
- William Beaumont Hospital
Royal Oak, Michigan, United States
|
|
| 6 |
NCT03796650 |
Not yet recruiting |
Fecal Transplantation for Primary Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Other: Fecal microbiota transplantation
- Drug: Vancomycin
|
Interventional
|
Phase 3 |
- Oslo University Hospital
- Frontier Science & Technology Research Foundation, Inc.
- South-Eastern Norway Regional Health Authority
- (and 3 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patients with durable cure
- Patients with durable cure with additional treatment.
- Treatment adverse events
- (and 2 more...)
|
188 |
All |
18 Years and older (Adult, Older Adult) |
NCT03796650 |
COLONIZE |
COLONIZE |
February 1, 2019 |
January 31, 2024 |
January 31, 2024 |
January 8, 2019 |
January 10, 2019 |
|
|
|
| 7 |
NCT03137173 |
Recruiting |
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections |
- Acute Bacterial Skin and Skin Structure Infections
|
- Drug: Ceftobiprole medocaril
- Drug: Vancomycin plus Aztreonam
|
Interventional
|
Phase 3 |
- Basilea Pharmaceutica
- Department of Health and Human Services
|
Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Objective early clinical response
- Investigator-assessed clinical success
|
674 |
All |
18 Years and older (Adult, Older Adult) |
NCT03137173 |
BPR-CS-008 |
|
February 20, 2018 |
October 2019 |
November 2019 |
May 2, 2017 |
January 11, 2019 |
|
- Physician Alliance Research Center
Anaheim, California, United States - Saint Joseph's Clinical Research
Anaheim, California, United States - eStudySite - Chula Vista - PPDS
Chula Vista, California, United States - (and 30 more...)
|
|
| 8 |
NCT03617445 |
Not yet recruiting |
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients |
- Clostridium Difficile Infection Recurrence
|
- Drug: FMT enema
- Drug: Oral Vancomycin
- Drug: FMT enema placebo
- Drug: Oral Vancomycin placebo
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Compare the rate of recurrence of CDI in solid organ transplant recipients with FMT compared with oral vancomycin
- CDI-related QOL
- Compare the change in gut microbiota and evaluate the association between the change in gut microbiota and recurrence of CDI
- (and 2 more...)
|
158 |
All |
18 Years and older (Adult, Older Adult) |
NCT03617445 |
2018-1056 |
|
February 1, 2019 |
December 31, 2023 |
December 31, 2023 |
August 6, 2018 |
December 28, 2018 |
|
- University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
|
|
| 9 |
NCT03839914 |
Not yet recruiting
New |
Does Vancomycin Reduce Surgical Site Infections in Spine Surgery |
- Spinal Degeneration
- Spinal Deformity
- Trauma
- (and 2 more...)
|
|
Interventional
|
Not Applicable |
- The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Surgical site infection rate
- Cost-effectiveness of vancomycin use
- Serum vancomycin level
- Renal function test
|
170 |
All |
Child, Adult, Older Adult |
NCT03839914 |
Study protocol 1.0 |
|
April 1, 2020 |
March 31, 2022 |
September 30, 2022 |
February 15, 2019 |
February 15, 2019 |
|
- Queen Mary Hospital
Hong Kong, Hong Kong
|
|
| 10 |
NCT03795233 |
Not yet recruiting |
Fecal Microbiota Transplant for Primary CDI |
- Clostridium Difficile Infection
|
- Biological: Fecal microbiota transplant G3 capsules
- Other: Oral Vancomycin alone
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Stool microbiome with and without FMT administration
- Feasibility of administering FMT after completion of a course of oral vancomycin therapy
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of FMT after a course of oral vancomycin therapy
- (and 4 more...)
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT03795233 |
H-37574 |
|
February 2019 |
February 2020 |
February 2020 |
January 7, 2019 |
January 7, 2019 |
|
- Boston Medical Center
Boston, Massachusetts, United States
|
|
| 11 |
NCT03412500 |
Recruiting |
Vancomycin Dosage Adjustment for MRSA Infections |
- Methicillin-Resistant Staphylococcus Aureus
|
- Drug: Vancomycin equation-based method
- Drug: Vancomycin trough concentration method
|
Interventional
|
Phase 4 |
- Pinyo Rattanaumpawan
- Siriraj Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical response
- Renal adverse event
|
114 |
All |
18 Years and older (Adult, Older Adult) |
NCT03412500 |
101/2559(EC1) |
|
October 2016 |
September 2018 |
September 2018 |
January 26, 2018 |
January 26, 2018 |
|
- Siriraj Hospital
Bangkok, Thailand
|
|
| 12 |
NCT03721328 |
Recruiting |
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation |
- Prosthetic Joint Infection
|
- Combination Product: vancomycin hydrochloride and tobramycin sulfate
|
Interventional
|
Phase 2 |
- Joint Purification Systems
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of successful subjects
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT03721328 |
JPS-001 |
|
October 26, 2018 |
February 2019 |
April 2019 |
October 26, 2018 |
November 6, 2018 |
|
- Sky Ridge Hospital
Lone Tree, Colorado, United States - Ortho Indy
Indianapolis, Indiana, United States - Covenant Hospital
Saginaw, Michigan, United States - (and 2 more...)
|
|
| 13 |
NCT02284126 |
Recruiting |
Topical Vancomycin for Neurosurgery Wound Prophylaxis |
- Infection
- Surgery
- Nervous System Diseases
|
|
Interventional
|
Phase 3 |
- Columbia University
- Agency for Healthcare Research and Quality (AHRQ)
- Cornell University
- Icahn School of Medicine at Mount Sinai
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Any surgical-site infection as evidenced by surgeon or attending physician diagnosis, or signs and symptoms of infection assessed by phone call interview or at in-office follow-up consultation
- Serum vancomycin levels
- Development of previously undetected vancomycin resistance
|
3600 |
All |
18 Years and older (Adult, Older Adult) |
NCT02284126 |
AAAN3703
1R01HS022903-01 |
Vanguard |
October 2014 |
October 2019 |
October 2019 |
November 5, 2014 |
February 17, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 14 |
NCT03402945 |
Recruiting |
Prevention of Infections in Cardiac Surgery (PICS) Prevena Study |
|
- Device: Prevena
- Drug: Cefazolin
- Drug: Vancomycin
- Other: standard wound dressing
|
Interventional
|
Phase 4 |
- Population Health Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Adherence to the wound management system
- Adherence to the antibiotic regimen
- Loss of follow-up
- (and 7 more...)
|
4000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03402945 |
PICS-PREVENA V1_20171106 |
PICS-Prevena |
March 5, 2018 |
April 2020 |
July 2020 |
January 18, 2018 |
September 5, 2018 |
|
- Hamilton General Hospital
Hamilton, Ontario, Canada - London Health Sciences Centre & Lawson Health Research Institute
London, Ontario, Canada
|
|
| 15 |
NCT02774382 |
Recruiting |
Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections |
|
- Drug: Vancomycin
- Drug: Fecal microbiota transplantation
- Drug: Rectal bacteriotherapy
|
Interventional
|
Phase 3 |
- Hvidovre University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical cure of recurrent Clostridium difficile infection defined as patient-reported abscence of Clostridium difficile infection 90 days after treatment.
- Early or late recurrence of CDI after the end of treatment defined as recurrence of symptoms of CDI and a positive stool sample with Clostridium difficile (PCR).
- Days with diarrhea
- (and 13 more...)
|
450 |
All |
18 Years and older (Adult, Older Adult) |
NCT02774382 |
SJ-478 |
|
May 1, 2017 |
December 2018 |
January 2019 |
May 17, 2016 |
September 27, 2017 |
|
- Hvidovre Hospital
Hvidovre, Denmark - Køge sygehus
Køge, Denmark
|
|
| 16 |
NCT02865616 |
Recruiting |
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) |
- Clostridium Difficile Infection
|
- Drug: MET-2
- Drug: Vancomycin
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To demonstrate clinical resolution of diarrhea with no CDI relapse,
- Incidence of adverse events (safety and tolerability)
- number of bowel movements (overall well-being)
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02865616 |
MET-2-101 |
|
October 27, 2017 |
March 15, 2018 |
December 2018 |
August 12, 2016 |
December 7, 2017 |
|
- Queen's University, Kingston General Hospital
Kingston, Ontario, Canada
|
|
| 17 |
NCT03250104 |
Recruiting |
Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives |
- Clostridium Difficile Infection
- VRE Infection
- Nosocomial Infection
- MRGN Bacteria
|
- Other: Infection Control
- Other: Antibiotic Stewardship
|
Observational
|
|
- University Hospital of Cologne
- Charite University, Berlin, Germany
- University Hospital Freiburg
- (and 3 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- CDI incidence
- Effectiveness of IC bundle through incidence of CDI or BSI by VRE and MRGN
- PPI usage
- (and 4 more...)
|
80000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03250104 |
TTU HAARBI 8.810 |
ABSOLUTE |
November 2016 |
December 2018 |
December 2020 |
August 15, 2017 |
October 16, 2018 |
|
- University Hospital of Cologne
Cologne, NRW, Germany
|
|
| 18 |
NCT02631408 |
Recruiting |
Intrawound Vancomycin Powder in Spinal Fusion Surgery |
|
|
Interventional
|
Phase 4 |
- Orthopedic Hospital Vienna Speising
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- SSI rate
- C-reactive protein
- Revision rate
|
440 |
All |
18 Years and older (Adult, Older Adult) |
NCT02631408 |
iVRCT1_4 |
iVRCT |
August 2015 |
December 2018 |
February 2019 |
December 16, 2015 |
October 5, 2017 |
|
- Orhopedic Hospital Speising
Vienna, Austria
|
|
| 19 |
NCT03053505 |
Recruiting |
A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Biological: faecal human microbiota transplant (FMT)
- Drug: Vancomycin or Fidaxomicin
|
Interventional
|
Not Applicable |
- Sejtterapia Kozpont Kft.
- University of Debrecen
- Kenézy Gyula Korhaz es Rendelointezet
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Global cure rate at 10 weeks
- Time to clinical cure
- Time to global cure
- (and 13 more...)
|
150 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03053505 |
FMT01 |
FMTREAT |
January 2017 |
December 2017 |
October 2018 |
February 15, 2017 |
March 30, 2017 |
|
- Miskolci Semmelweis Korhaz es Egyetemi Oktatokorhaz
Miskolc, B-A-Z County, Hungary - University of Debrecen, Clinical Centre
Debrecen, Hajdu-Bihar megye, Hungary - Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
Nyiregyhaza, Szabocs-Szatmar-Bereg megye, Hungary
|
|
| 20 |
NCT03308253 |
Recruiting |
Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection |
|
- Device: Stimulan Rapid Cure
- Drug: Vancomycin
- Drug: Tobramycin
- Other: Standard of Care
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Surgical Site Infection
- Wound Complication Rate
- Surgical Graft Infection Rate
- Bacterial Resistance
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03308253 |
Antimicrobial Beads |
|
July 16, 2018 |
June 2019 |
July 2019 |
October 12, 2017 |
July 19, 2018 |
|
- Hamilton General Hospital
Hamilton, Ontario, Canada
|
|
| 21 |
NCT02686645 |
Not yet recruiting |
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Biological: Fecal Microbiota
- Drug: vancomycin
- Drug: Loperamide
- Drug: metronidazole
|
Interventional
|
Phase 2
Phase 3 |
- Queen Elizabeth II Health Sciences Centre
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Resolution of CDI
- Success of treatment
- Adverse effects
- (and 3 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02686645 |
NSHA REB File #: 1020563 |
|
December 2016 |
December 2021 |
December 2021 |
February 19, 2016 |
September 27, 2016 |
|
|
|
| 22 |
NCT02216227 |
Recruiting |
Checklist to Prevent MRSA Surgical Site Infections |
|
- Drug: Mupirocin
- Drug: Chlorhexidine gluconate
- Drug: Cefazolin
- (and 2 more...)
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Superficial and deep/organ space MRSA infections
- Compliance with the entire pre-surgical bundle and individual bundle components
- Length of postoperative stay
- (and 3 more...)
|
10748 |
All |
18 Years and older (Adult, Older Adult) |
NCT02216227 |
CRE 12-291 |
|
April 1, 2014 |
September 30, 2019 |
September 30, 2019 |
August 13, 2014 |
December 21, 2018 |
|
- Miami VA Healthcare System, Miami, FL
Miami, Florida, United States - Iowa City VA Health Care System, Iowa City, IA
Iowa City, Iowa, United States - Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland, United States - (and 8 more...)
|
|
| 23 |
NCT00945152 |
Recruiting |
Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM) |
- Bacterial Infections
- Wounds
|
- Drug: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)
- Drug: Placebo, complex gel formulation without Vancomycin
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Eliminate MRSA infection
- More rapid healing of cSSTI
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT00945152 |
WIRB study # 1111446
None yet, self funding |
Vancogel(R) |
July 2011 |
December 2019 |
December 2019 |
July 23, 2009 |
August 7, 2018 |
|
- Robert S Berman MD / 2141 Alt. A1A South, Suite 450
Jupiter, Florida, United States
|
|
| 24 |
NCT03827447 |
Not yet recruiting
New |
Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile |
- Clostridium Difficile Infection
|
- Drug: Vancomycin Oral Capsule
- Drug: Placebo Oral Capsule
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Determine the change in C. difficile loads between the vancomycin vs. placebo group.
- Determine the long-term persistence of C. difficile from the change in qPCR levels between the vancomycin vs. placebo group
- Characterize the change on structural alterations of the microbiome after end of treatment between the vancomycin vs. placebo groups through 16S rRNA sequencing.
- (and 5 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03827447 |
PRO00033844 |
|
February 2019 |
February 2019 |
February 2021 |
February 1, 2019 |
February 1, 2019 |
|
|
|
| 25 |
NCT03426761 |
Recruiting |
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections |
- Bone Infection
- Osteomyelitis
- Septic Arthritis
- (and 2 more...)
|
- Drug: Dalbavancin
- Drug: Vancomycin
|
Interventional
|
Phase 4 |
- Infectious Diseases Physicians, Inc.
- Johns Hopkins University
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical response (non-failure) to assigned treatment at day #42
- Sustained Clinical Response at day #90
- Sustained Clinical Response at day #180
- (and 4 more...)
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03426761 |
IIT-2017-10117 |
|
January 25, 2018 |
July 2020 |
January 2021 |
February 8, 2018 |
February 4, 2019 |
|
- Infectious Diseases Physicians, Inc.
Annandale, Virginia, United States
|
|
| 26 |
NCT03713528 |
Not yet recruiting |
How to Improve the Results of Irrigation and Debridement for PJI Through the Use of Intraosseous Antibiotics |
|
- Drug: Intraoperative Intraosseous Vancomycin
|
Interventional
|
Phase 4 |
- OrthoCarolina Research Institute, Inc.
- American Association of Hip and Knee Surgeons
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
212 |
All |
18 Years and older (Adult, Older Adult) |
NCT03713528 |
HK213 |
|
December 1, 2018 |
January 1, 2022 |
June 1, 2022 |
October 19, 2018 |
October 19, 2018 |
|
|
|
| 27 |
NCT02814916 |
Recruiting |
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
- Methicillin-Resistant Staphylococcus Aureus
- Bacterial Infections
- Staphylococcal Skin Infections
|
- Drug: Dalbavancin single dose
- Drug: Dalbavancin two dose
- Drug: Comparator
|
Interventional
|
Phase 3 |
- Durata Therapeutics Inc., an affiliate of Allergan plc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with abnormal audiologic assessment
- Change in number of patients with the presence of either Clostridium difficile (CD), vancomycin-resistant enterococci (VRE), or both CD and VRE in bowel flora
- Clinical response
- (and 11 more...)
|
300 |
All |
3 Months to 17 Years (Child) |
NCT02814916 |
DUR001-306
2014-005281-30 |
|
March 30, 2017 |
January 25, 2019 |
January 25, 2019 |
June 28, 2016 |
June 7, 2018 |
|
- University of South Alabama
Mobile, Alabama, United States - Maricopa Integrated Health System
Phoenix, Arizona, United States - Southbay Pharma Research
Buena Park, California, United States - (and 40 more...)
|
|
| 28 |
NCT03030248 |
Not yet recruiting |
Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population |
- Clostridium Difficile Infection
|
- Drug: Vancomycin Oral Capsule
- Drug: Placebo Oral Capsule
|
Interventional
|
Phase 4 |
- Medical College of Wisconsin
- The Jackson Laboratory for Genomic Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Changes in Clostridium difficile bacterial loads in the stool
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03030248 |
PRO00028749 |
|
February 1, 2018 |
May 31, 2019 |
May 31, 2019 |
January 24, 2017 |
November 30, 2017 |
|
|
|
| 29 |
NCT03438214 |
Not yet recruiting |
Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients |
- Gram-Positive Bacterial Infections
- Nephrotoxicity
- Sepsis
|
- Drug: Vancomycin Continuous infusion
- Drug: Vancomycin Intermittent infusion
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Acute renal failure
- Hypersensibility reactions with vancomycin
- Length of ICU stay
- (and 3 more...)
|
222 |
All |
18 Years and older (Adult, Older Adult) |
NCT03438214 |
81226617.8.1001.0065 |
ETERNITY |
April 28, 2018 |
February 28, 2020 |
December 1, 2022 |
February 19, 2018 |
April 5, 2018 |
|
- Faculty of Medicine University os São Paulo
São Paulo, SP, Brazil
|
|
| 30 |
NCT02285140 |
Recruiting |
Prevention of Infections in Cardiac Surgery |
- Thoracic Surgery
- Antibiotic Prophylaxis
|
- Drug: Cefazolin
- Drug: Vancomycin
|
Interventional
|
Not Applicable |
- Hamilton Health Sciences Corporation
- The Physicians' Services Incorporated Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Proportion of patients receiving antibiotics according to study protocol
- Proportion of patients with complete follow-up, i.e. up to 90 days or death; goal >95%
- Agreement of blinded outcome assessment based on information from the case report form
- (and 4 more...)
|
3000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02285140 |
PICS |
PICS |
April 2015 |
June 2020 |
October 2020 |
November 6, 2014 |
December 6, 2018 |
|
- Hamilton Health Sciences
Hamilton, Ontario, Canada - St. Michael's Hospital
Toronto, Ontario, Canada - University of Sherbrook
Sherbrook, Quebec, Canada
|
|
| 31 |
NCT03181932 |
Recruiting |
A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients |
|
- Drug: Vancomycin inhalation powder
- Drug: Placebo inhalation powder
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Absolute change in FEV1 percent predicted
- Time to first pulmonary exacerbation
- Frequency of pulmonary exacerbations
- (and 5 more...)
|
200 |
All |
6 Years and older (Child, Adult, Older Adult) |
NCT03181932 |
SAV005-04 |
|
September 26, 2017 |
June 15, 2019 |
December 15, 2019 |
June 9, 2017 |
January 4, 2019 |
|
- Pulmonary Associates of Mobile
Mobile, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 75 more...)
|
|
| 32 |
NCT03456544 |
Not yet recruiting |
Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China |
- Vancomycin
- Staphylococcal Infections
- Adverse Effect
- (and 2 more...)
|
|
Observational
|
|
- Peking University First Hospital
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Retrospective
|
- Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate
- VAN-AKI detection rate
- TDM detction rate
- (and 2 more...)
|
10000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03456544 |
20180122 |
|
July 31, 2018 |
March 31, 2019 |
May 31, 2019 |
March 7, 2018 |
May 22, 2018 |
|
|
|
| 33 |
NCT01373112 |
Recruiting |
Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection |
- Osteoarthritis
- Knee Infection
- Prosthetic Joint Infection
- (and 2 more...)
|
- Procedure: Static Spacer
- Procedure: Articulating Spacer
|
Interventional
|
Not Applicable |
- Rush University Medical Center
- Central DuPage Hospital
- Joint Implant Surgeons, Inc.
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Range of motion
- Knee Society Score
- Operative time
|
140 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT01373112 |
SPACERKNEE |
|
December 2011 |
August 2020 |
August 2020 |
June 14, 2011 |
August 28, 2018 |
|
- Rush University Medical Center
Chicago, Illinois, United States
|
|
| 34 |
NCT03485950 |
Recruiting |
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam |
- Other Infectious Diseases
|
- Drug: Ceftolozane-Tazobactam
- Drug: Cefepime
- Drug: Meropenem
- Drug: Piperacillin/Tazobactam
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV)
- Safety of Combination Therapy of E7070, Idarubicin and Cytarabine Determined by Version 4.03 of the Common Toxicity Criteria for Adverse Events
- Primary Efficacy Parameter of Combination Therapy of E7070, Idarubicin and Cytarabine
- (and 5 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03485950 |
2017-0729
NCI-2018-00755 |
|
May 16, 2018 |
May 2019 |
May 2019 |
April 3, 2018 |
November 5, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 35 |
NCT02764359 |
Recruiting |
Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens |
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to attain therapeutic vancomycin concentrations
- Reported adverse events
- Examine the pharmacokinetic parameter of elimination rate constant (ke) following the loading vancomycin dose
- (and 4 more...)
|
128 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02764359 |
15-120 |
|
August 2016 |
August 2019 |
August 2019 |
May 6, 2016 |
October 9, 2018 |
|
- CAMC Health Systems
Charleston, West Virginia, United States
|
|
| 36 |
NCT03643887 |
Not yet recruiting |
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients |
- Clostridium Difficile Infection
|
- Drug: FMT Capsule DE
- Drug: Placebo oral capsule
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Compare incidence of VRE/CRE decolonization between FMT Capsule double encapsuled (DE) and placebo
- VRE/CRE infection at Day 3, Day 10, and Week 4 following randomization.
- Microbial engraftment assessed by microbial disruption index (MDI) at Day 3, Day 10, and Week 4 following randomization
- (and 3 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT03643887 |
W81XWH18PRMPCTA |
|
July 1, 2019 |
June 1, 2022 |
June 30, 2022 |
August 23, 2018 |
August 23, 2018 |
|
|
|
| 37 |
NCT01792804 |
Recruiting |
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options |
- Staphylococcus Aureus Infection
|
- Drug: Trimethoprim-Sulfamethoxazole
- Drug: Clindamycin
- Drug: Linezolid
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Heinrich-Heine University, Duesseldorf
- German Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- SAB-related complications
- Length of hospital stay
- Survival
- Complications of intravenous therapy
|
215 |
All |
18 Years and older (Adult, Older Adult) |
NCT01792804 |
Uni-Koeln-1400
2013-000577-77 |
SABATO |
December 2013 |
October 2019 |
October 2019 |
February 15, 2013 |
October 22, 2018 |
|
- Annecy
Annecy, France - Chambéry
Chambéry, France - Grenoble
Grenoble, France - (and 39 more...)
|
|
| 38 |
NCT03697096 |
Recruiting |
The INSPIRE-ASP UTI Trial |
- Urinary Tract Infection (UTI)
|
- Other: Routine Care
- Other: INSPIRE CPOE Smart Prompt
|
Interventional
|
Not Applicable |
- Harvard Pilgrim Health Care
- Hospital Corporation of America Healthcare (HCA)
- University of California, Irvine
- (and 3 more...)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Proportion of Days with Empiric Extended-Spectrum (ES) Antibacterial Treatment for UTI
- Proportion of Days with Empiric Vancomycin Treatment for UTI
- Proportion of Days with Empiric Antipseudomonal Treatment for UTI
|
59 |
All |
18 Years and older (Adult, Older Adult) |
NCT03697096 |
PH000619B_UTI |
|
October 1, 2018 |
June 30, 2022 |
June 30, 2024 |
October 5, 2018 |
October 29, 2018 |
|
- Riverside Community Hospital
Riverside, California, United States - Regional Medical Center of San Jose
San Jose, California, United States - Los Robles Regional Medical Center
Thousand Oaks, California, United States - (and 56 more...)
|
|
| 39 |
NCT03617172 |
Recruiting |
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol |
|
- Drug: Misoprostol 100Mcg Tab
- Other: Placebo
|
Interventional
|
Phase 2 |
- Vanderbilt University Medical Center
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Rate of clinical recurrence of CDI in patients aged 50 years or older during the first 8 weeks after vancomycin therapy is stopped.
- Number of recurrences during the follow-up period
- Time to resolution of diarrhea
|
440 |
All |
50 Years and older (Adult, Older Adult) |
NCT03617172 |
172163
U01TR002398 |
PROCLAIM |
November 26, 2018 |
November 2022 |
November 2024 |
August 6, 2018 |
January 11, 2019 |
|
- Washington University
Saint Louis, Missouri, United States - University of North Carolina
Chapel Hill, North Carolina, United States - Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 40 |
NCT02466698 |
Recruiting |
Intestinal Lavage for the Treatment of Severe C. Difficile Infections |
|
- Procedure: Intestinal Lavage
- Drug: Vancomycin
- Drug: PEG
- Drug: Metronidazole
|
Interventional
|
Phase 2
Phase 3 |
- Lawson Health Research Institute
- London Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of eligible participants recruited into the study
- Number of participants meeting study inclusion criteria
- Number of participants who complete the assigned study protocol
- (and 6 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02466698 |
106184 |
|
August 2016 |
August 2019 |
August 2019 |
June 9, 2015 |
August 13, 2018 |
|
- London Health Sciences Centre
London, Ontario, Canada
|
|
| 41 |
NCT02609646 |
Recruiting |
AbioKin - Antibiotic Kinetics |
- Critical Illness
- Infection
|
- Drug: Linezolid
- Drug: Meropenem
- Drug: Piperacillin-tazobactam combination product
- Drug: Vancomycin
|
Observational
|
|
- Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Drug plasma concentration (time-dependent antibiotics)
- Drug plasma concentration (concentration-dependent antibiotics)
|
1500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02609646 |
AbioKin |
|
January 2016 |
December 2019 |
June 2020 |
November 20, 2015 |
February 15, 2019 |
|
- Ospedale Maurizio Bufalini, UO Anestesia Terapia Intensiva
Cesena, Emilia Romagna, Italy - Ospedale S. Giovanni di Dio ASL 10, Servizio Anestesia e Rianimazione
Firenze, FI, Italy - Ospedale San Giovanni di Dio
Orbetello, Grosseto, Italy - (and 8 more...)
|
|
| 42 |
NCT03765528 |
Not yet recruiting |
Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens |
- Patients at High Risk of Antibacterial Treatment Upon Admission
|
|
Observational
|
|
- University Hospital of Cologne
- University Hospital of North Norway
- Karolinska Institutet
- (and 7 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Impact of inappropriate antibacterial prescription on intestinal microbiota domination by healthcare associated pathogens
- Time-point of Intestinal Colonization
- Time-point of Intestinal Domination
- (and 4 more...)
|
1500 |
All |
18 Years and older (Adult, Older Adult) |
NCT03765528 |
PILGRIM |
PILGRIM |
December 1, 2018 |
December 31, 2020 |
March 31, 2021 |
December 5, 2018 |
December 5, 2018 |
|
- University Hospital of Cologne
Cologne, NRW, Germany
|
|
| 43 |
NCT02667418 |
Recruiting |
Optimal Treatment for Recurrent Clostridium Difficile |
- Clostridium
- Difficile
- Fidaxomicin
- Vancomycin
|
- Drug: Fidaxomicin
- Drug: Vancomycin with Taper/Pulse
- Drug: Vancomycin
|
Interventional
|
Phase 4 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Determine symptom resolution during treatment without any of the following: diarrhea recurrence; other non-fatal clinical events including severe abdominal pain, toxic megacolon, and colectomy; and death.
- CDI Composite outcome measure
|
546 |
All |
18 Years and older (Adult, Older Adult) |
NCT02667418 |
596
#15-03 |
OpTION |
December 21, 2015 |
May 31, 2022 |
May 31, 2022 |
January 28, 2016 |
January 4, 2019 |
|
- Phoenix VA Health Care System, Phoenix, AZ
Phoenix, Arizona, United States - Southern Arizona VA Health Care System, Tucson, AZ
Tucson, Arizona, United States - Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR
Little Rock, Arkansas, United States - (and 24 more...)
|
|
| 44 |
NCT03349268 |
Recruiting |
Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection |
- Healthcare Associated Infection
- Clostridium Difficile Infection
- Infection Due to Multidrug Resistant Bacteria
|
- Device: Pulsed UV Device
- Device: Sham Device
|
Interventional
|
Not Applicable |
- University of Michigan
- Agency for Healthcare Research and Quality (AHRQ)
- Xenex Disinfection Services LLC
- (and 4 more...)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Reduction in the number of environmentally-implicated Healthcare-Associated Infections (eiHAIs) associated with the additional use of a PX-UV disinfection to standard terminal cleaning.
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT03349268 |
1R01HS024709-01 |
|
July 7, 2017 |
May 2022 |
May 2022 |
November 21, 2017 |
November 27, 2018 |
|
- Detroit Medical Center
Detroit, Michigan, United States
|
|
| 45 |
NCT03723551 |
Not yet recruiting |
Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus |
|
|
Interventional
|
Phase 2 |
- Debiopharm International SA
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs) and Serious Adverse Event (SAEs) Based on Nature, Incidence, Severity, Seriousness, and Outcome
- Change From Baseline in Number of Participants With Incidence of Laboratory Abnormalities at Week 24
- Proportion of Participants With Clinical Response at Day 8, 28, 42, 84, 112 and 168
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03723551 |
Debio 1450-BJI-205
2017-002854-35 |
|
January 30, 2019 |
November 1, 2019 |
November 1, 2019 |
October 29, 2018 |
January 29, 2019 |
|
- Midland Florida Clinical Research Center
DeLand, Florida, United States - Cherkasy Regional Hospital of Cherkasy Oblast Council
Cherkasy, Ukraine - Dnipropetrovsk Regional Clinical Hospital
Dnipropetrovs'k, Ukraine - (and 4 more...)
|
|
| 46 |
NCT03176134 |
Recruiting |
A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) |
- Acute Bacterial Skin and Skin Structure Infections
|
- Drug: MK-1986
- Drug: Comparator
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Adverse Events
- Study Discontinuations due to an Adverse Event
- Hematopoietic Cytopenias
- Clinical Success
|
120 |
All |
up to 11 Years (Child) |
NCT03176134 |
1986-018
2016-003884-20
MK-1986-018 |
|
January 20, 2019 |
August 20, 2021 |
September 18, 2021 |
June 5, 2017 |
February 15, 2019 |
|
- Rady Children's Hospital-San Diego ( Site 0118)
San Diego, California, United States - Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0129)
Chicago, Illinois, United States - Children's Hospital of Michigan ( Site 0100)
Detroit, Michigan, United States - (and 10 more...)
|
|
| 47 |
NCT01373099 |
Recruiting |
Study of Antibiotic Spacer Design to Treat Infection After Hip Replacement |
- Osteoarthritis
- Hip Infection
- Prosthetic Joint Infection
- (and 2 more...)
|
- Procedure: Implantation of a static, non-articulating cement spacer.
- Procedure: Implantation of an articulating spacer.
|
Interventional
|
Not Applicable |
- Rush University Medical Center
- Thomas Jefferson University
- Central DuPage Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Harris Hip Score
- Operative time
- Hip dislocation rates
|
80 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT01373099 |
SPACERHIP |
SPACERHIP |
August 2011 |
August 2020 |
August 2020 |
June 14, 2011 |
August 28, 2018 |
|
- Rush University Medical Center
Chicago, Illinois, United States
|
|
| 48 |
NCT03432858 |
Not yet recruiting |
Preoperative Antibiotics for Carpal Tunnel Release Surgery |
|
- Drug: Vancomycin
- Drug: Cefazolin
- Drug: Saline Solution
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Surgical Site Infection
- Diabetes diagnosis
- Tobacco use
- (and 9 more...)
|
650 |
All |
18 Years and older (Adult, Older Adult) |
NCT03432858 |
Prophylactic Antibiotics: ESCR |
|
February 2018 |
December 2021 |
December 2022 |
February 14, 2018 |
February 14, 2018 |
|
- WellSpan Surgery and Rehab Hospital
York, Pennsylvania, United States
|
|
| 49 |
NCT03372941 |
Not yet recruiting |
Hospital Avoidance Strategies for ABSSSI |
|
|
Interventional
|
Phase 4 |
- Washington University School of Medicine
- Barnes-Jewish Hospital
- Allergan
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Healthcare utilization related to ABSSSI
- Healthcare cost related to ABSSSI management
- Clinical response
- (and 5 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03372941 |
201709136 |
|
November 1, 2018 |
September 1, 2019 |
December 1, 2019 |
December 14, 2017 |
October 3, 2018 |
|
|
|
| 50 |
NCT03760484 |
Not yet recruiting |
Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection |
|
- Drug: Fidaxomicin 200 mg
- Biological: fecal microbiota transplantation (FMT)
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- resolution of diarrhea or return of bowel habit to baseline by Bristol stool scale
- mortality
- sustained resolution of diarrhea or return of bowel habit to baseline by Bristol stool scale
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03760484 |
Pro00081229 |
|
December 16, 2018 |
December 16, 2020 |
March 16, 2022 |
November 30, 2018 |
November 30, 2018 |
|
|
|
| 51 |
NCT02901717 |
Recruiting |
Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI |
- Catheter-related Infections
|
- Drug: Mino-Lok
- Drug: Antibiotic lock
|
Interventional
|
Phase 3 |
- Leonard-Meron Biosciences, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of subjects deemed successfully treated at the end of the study period
- Proportion of subjects with a response of Clinical Cure at End of Treatment.
- Proportion of subjects in the MITT and CE Populations with a response of microbiological eradication.
- (and 2 more...)
|
700 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT02901717 |
MDA-2013-0039 |
|
February 13, 2018 |
June 2019 |
September 2019 |
September 15, 2016 |
July 10, 2018 |
|
- University of Colorado Denver
Aurora, Colorado, United States - Georgetown University Hospital
Washington, District of Columbia, United States - University of Chicago
Chicago, Illinois, United States - (and 9 more...)
|
|
| 52 |
NCT03481569 |
Recruiting |
Population Pharmacokinetic-pharmacodynamic (PK-PD) Study of 7 Broad-Spectrum Anti-infective Agents in the Cerebro Spinal Fluid (CSF) of Brain Injured Patients With an External Ventricular Drainage (EVD). |
|
- Other: Blood and cerebrospinal fluid pharmacocinetic samples on one of the seven antibiotics prescribed in routine use
|
Interventional
|
Phase 1 |
- Poitiers University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- CSF-to-plasma area under the unbound concentration-time curve for each antibiotic
- Time > Minimal Inhibitrice Concentration for each antibiotic
- Area Under the Curve / Minimal Inhibitrice Concentration for each antibiotic
- Peak concentration / Minimal Inhibitrice Concentration for each antibiotic
|
175 |
All |
18 Years and older (Adult, Older Adult) |
NCT03481569 |
PKpop LCR |
|
July 6, 2018 |
July 2020 |
October 2020 |
March 29, 2018 |
October 30, 2018 |
|
- CHU of Poitiers
Poitiers, France
|
|
| 53 |
NCT03685747 |
Recruiting |
Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis |
- Peritoneal Dialysis-associated Peritonitis
|
|
Interventional
|
Phase 1 |
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Maximum total plasma concentration (Cmax)
- Time to maximum plasma concentration (Tmax)
- Area under the concentration-time curve (AUC0-T)
- (and 3 more...)
|
4 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03685747 |
12451 |
|
November 2018 |
March 2019 |
May 2019 |
September 26, 2018 |
September 26, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 54 |
NCT03586362 |
Recruiting |
Vancomycin De-escalation Therapy in Patients With Pneumonia |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of Clinical Improvement
- Hospital Length of Stay
- In-hospital mortality
- (and 3 more...)
|
278 |
All |
18 Years and older (Adult, Older Adult) |
NCT03586362 |
17-406 |
|
February 8, 2018 |
June 30, 2019 |
December 30, 2019 |
July 13, 2018 |
July 13, 2018 |
|
- Charleston Area Medical Center
Charleston, West Virginia, United States
|
|
| 55 |
NCT03688659 |
Not yet recruiting |
Vancomycin, Gentamycin in Infective Endocarditis |
|
- Drug: Vancomycin and gentamycin
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- vancomycin and gentamycin in infective endocarditis
|
30 |
All |
up to 18 Years (Child, Adult) |
NCT03688659 |
vgie |
|
January 1, 2019 |
January 1, 2021 |
January 1, 2021 |
September 28, 2018 |
September 28, 2018 |
|
|
|
| 56 |
NCT03087890 |
Recruiting |
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria |
- HIV-1-infection
- Pneumocystis Pneumonia
- Opportunistic Infections
- (and 2 more...)
|
- Drug: Cotrimoxazole
- Drug: Placebo
|
Interventional
|
Phase 4 |
- University of Bergen
- Haukeland University Hospital
- Muhimbili University of Health and Allied Sciences
- Helse Vest
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in carriage of resistant bacteria in gut and/or nose by week 2
- Change in carriage of resistant bacteria in gut and/or nose by week 24
- Change in carriage of resistant bacteria in gut and/or nose by week 48
- (and 3 more...)
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT03087890 |
REK2015/540
TZ16CT007
NIMRlHQ/R.SaJVol. 1X12144
2015-10-27/AEC/Vol.X/54 |
CoTrimResist |
March 30, 2017 |
October 30, 2018 |
October 30, 2018 |
March 23, 2017 |
April 5, 2018 |
|
- Amana Regional Referral Hospital
Dar es Salaam, Tanzania - Mbagala District Hospital
Dar es Salaam, Tanzania - Mnazimmoja Health Centre
Dar Es Salaam, Tanzania - (and 3 more...)
|
|
| 57 |
NCT02590523 |
Not yet recruiting |
Intracameral Antibiotic Safety Study |
- Intracameral Antibiotics
- Cataract Surgery
- Phacoemulsification
- (and 3 more...)
|
- Drug: Vancomycin
- Drug: Moxifloxacin
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Occurrence of adverse event
- Postoperative visual acuity measured by best spectacle corrected
|
500 |
All |
30 Years to 100 Years (Adult, Older Adult) |
NCT02590523 |
3 |
|
January 2019 |
January 2021 |
January 2021 |
October 29, 2015 |
April 4, 2018 |
|
|
|
| 58 |
NCT03765567 |
Not yet recruiting |
Placement of Antibiotic Powder in Wounds During the Emergency Room |
|
|
Interventional
|
Phase 4 |
- The University of Texas Health Science Center at San Antonio
- United States Army Institute of Surgical Research
- San Antonio Military Medical Center
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Deep-space infection rate at prophylaxis site
- Superficial infection rate requiring post-operative medical intervention
- Unplanned repeat visit rate
- (and 2 more...)
|
200 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT03765567 |
HSC2018-0520H |
POWDER |
February 28, 2019 |
January 2022 |
January 2023 |
December 5, 2018 |
January 24, 2019 |
|
- University Hospital
San Antonio, Texas, United States - San Antonio Military Medical Center
San Antonio, Texas, United States
|
|
| 59 |
NCT02922816 |
Recruiting |
FMT for MDRO Colonization After Infection in Renal Transplant Recipients |
- Infection Due to Resistant Organism
|
- Biological: Fecal Microbiota Transplant (FMT)
- Procedure: Bowel preparation
- Procedure: Stool or perirectal swab sampling
- Other: Fasting
|
Interventional
|
Phase 1 |
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The safety and feasibility of using FMT in adult participants with Target MDRO colonization after infection will be measured by comparing the number of adverse events (assessed by CTCAE v4.0) after Day 1 of each cycle as compared to baseline.
- Determine the rate of Target MDRO colonization between the control and experimental arms at screening and on Day 36 of each cycle.
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02922816 |
IRB00090101 |
PREMIX |
December 1, 2016 |
June 2019 |
December 2019 |
October 4, 2016 |
September 24, 2018 |
|
- Emory University Hospital
Atlanta, Georgia, United States
|
|
| 60 |
NCT03557008 |
Recruiting |
Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics |
|
- Biological: Rabies Vaccine
- Drug: Metronidazole
- Drug: Vancomycin
- Drug: Neomycin Sulfate
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
|
40 |
All |
18 Years to 49 Years (Adult) |
NCT03557008 |
IRB00101567 |
|
July 5, 2018 |
December 2022 |
December 2022 |
June 14, 2018 |
July 19, 2018 |
|
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States - The Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, United States
|
|
| 61 |
NCT02790996 |
Recruiting |
Neonatal Vancomycin Trial |
- Late Onset Neonatal Sepsis
|
|
Interventional
|
Phase 2 |
- PENTA Foundation
- St George's, University of London
- Institut National de la Santé Et de la Recherche Médicale, France
- (and 10 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Successful outcome at Test of Cure visit
- Clinically or microbiologically significant relapse or new infection requiring treatment with any other antibiotic for more than 24 hours
- Successful outcome at Visit 4 or End of Actual Vancomycin Therapy including total duration of vancomycin therapy
- (and 9 more...)
|
300 |
All |
up to 90 Days (Child) |
NCT02790996 |
NeoVanc |
NeoVanc |
February 27, 2017 |
December 1, 2018 |
February 1, 2019 |
June 6, 2016 |
June 29, 2018 |
|
- Tallinn's Children's Hospital
Tallinn, Estonia - Paediatric Intensive Care Unit, Clinicum of the University of Tartu
Tartu, Estonia - Aghia Sophia Children's Hospital (A)
Athens, Greece - (and 19 more...)
|
|
| 62 |
NCT02743585 |
Recruiting |
Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT) |
- Bacteremia
- Sepsis
- Fungemia
- Blood Stream Infection
|
- Device: Filmarray Blood Culture ID (BCID) panel
- Device: Rosco Diagnostica ESBL/carbapenemase screen kit
|
Interventional
|
Not Applicable |
- Tan Tock Seng Hospital
- Mayo Clinic
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Time from positive blood culture result to effective/optimal antibiotics
- Clinical outcome (Infection related mortality)
- Clinical outcome (All-cause related mortality)
- (and 12 more...)
|
832 |
All |
21 Years to 103 Years (Adult, Older Adult) |
NCT02743585 |
2015/00255 |
RABbIT |
March 20, 2017 |
June 2019 |
June 2019 |
April 19, 2016 |
May 11, 2018 |
|
- Tan Tock Seng Hospital
Singapore, Singapore
|
|
| 63 |
NCT03439124 |
Recruiting |
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia |
- Community-acquired Pneumonia
- Hospital-acquired Pneumonia
|
- Drug: Ceftobiprole medocaril
- Drug: Ceftazidime
- Drug: Ceftriaxone
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of adverse events
- Clinical cure at the TOC visit
- Microbiological eradication at the TOC visit
- (and 4 more...)
|
250 |
All |
3 Months to 17 Years (Child) |
NCT03439124 |
BPR-PIP-002 |
|
November 27, 2017 |
December 2019 |
December 2019 |
February 20, 2018 |
February 20, 2018 |
|
- Investigational Site
Pleven, Bulgaria - Investigational Site
Plovdiv, Bulgaria - Investigational Site
Ruse, Bulgaria - (and 7 more...)
|
|
| 64 |
NCT02701595 |
Recruiting |
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus |
|
- Drug: Amoxicillin
- Procedure: Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
|
Interventional
|
Phase 3 |
- University Hospital, Tours
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment failure
- Death from all-cause
- number of symptomatic embolic events
- (and 16 more...)
|
324 |
All |
18 Years and older (Adult, Older Adult) |
NCT02701595 |
RODEO 2 |
|
March 2016 |
October 2019 |
October 2019 |
March 8, 2016 |
September 27, 2018 |
|
- Service des maladies infectieuses, Centre Hospitalier du Pays d'Aix
Aix en Provence, France - Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès
Alès, France - Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens
Amiens, France - (and 50 more...)
|
|
| 65 |
NCT03157388 |
Recruiting |
The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis. |
|
- Drug: Combined Vancomycin and Gentamycin and Meropenem
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Macrophage activation cd163
- LBP
- TNF alfa
- Interleukin-1b
|
15 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03157388 |
1-10-72-1-15 |
|
June 1, 2017 |
November 1, 2017 |
November 1, 2017 |
May 17, 2017 |
September 28, 2017 |
|
- Aarhus University Hospital
Aarhus, Denmark
|
|
| 66 |
NCT03802461 |
Not yet recruiting |
Effectiveness of Fecal Flora Alteration for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization |
|
- Biological: Fecal Microbiota Transplantation (FMT)
|
Interventional
|
Phase 2
Phase 3 |
- Susy Hota
- Sinai Health System, Ontario, Canada
- University of Toronto, Ontario, Canada
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of intestinal colonization of patients with CPE 3 months after intervention.
- Randomization rate in study
- Proportion of patients retained in study for up to 6 months
- (and 6 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03802461 |
18-5177 |
EFFECT-CPE |
February 1, 2019 |
July 15, 2020 |
December 20, 2020 |
January 14, 2019 |
January 14, 2019 |
|
- William Osler Health System
Brampton, Ontario, Canada - Joseph Brant Hospital
Burlington, Ontario, Canada - Lakeridge Health
Oshawa, Ontario, Canada - (and 10 more...)
|
|
| 67 |
NCT03697070 |
Recruiting |
The INSPIRE-ASP PNA Trial |
|
- Other: INSPIRE CPOE Smart Prompt
- Other: Routine Care
|
Interventional
|
Not Applicable |
- Harvard Pilgrim Health Care
- Hospital Corporation of America Healthcare (HCA)
- University of California, Irvine
- (and 3 more...)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Proportion of Days with Empiric Extended-Spectrum (ES) Antibacterial Treatment for Pneumonia
- Proportion of Days with Empiric Vancomycin Treatment for Pneumonia
- Proportion of Days with Empiric Antipseudomonal Treatment for Pneumonia
|
59 |
All |
18 Years and older (Adult, Older Adult) |
NCT03697070 |
PH000619B_PNA |
|
October 1, 2018 |
June 30, 2022 |
June 30, 2024 |
October 5, 2018 |
October 29, 2018 |
|
- Riverside Community Hospital
Riverside, California, United States - Regional Medical Center of San Jose
San Jose, California, United States - Los Robles Regional Medical Center
Thousand Oaks, California, United States - (and 56 more...)
|
|
| 68 |
NCT01431326 |
Recruiting |
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care |
- Adenovirus
- Anesthesia
- Anxiety
- (and 47 more...)
|
- Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
|
Observational
|
|
- Daniel Benjamin
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The EMMES Corporation
- Duke University
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite of pharmacokinetic outcomes for understudied drugs in children
- Composite pharmacodynamic outcomes of understudied drugs in children
- Biomarkers associated with understudied drugs in children
|
10000 |
All |
up to 21 Years (Child, Adult) |
NCT01431326 |
Pro00029638
IND 113645
IND 114369
IND 114531
IND 118358
HHSN20100006
HHSN27500020
HHSN27500027
HHSN27500043
HHSN27500049 |
PTN_POPS |
November 2011 |
February 2020 |
February 2020 |
September 9, 2011 |
April 4, 2018 |
|
- Alaska Native Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - University of California at San Diego Medical Center
La Jolla, California, United States - (and 51 more...)
|
|
| 69 |
NCT03120975 |
Recruiting |
Computerized Antibiotic Stewardship Study |
|
- Other: Computerized decision support and audit & feedback
- Other: Audit & Feedback
- Other: Standard antibiotic stewardship
|
Interventional
|
Not Applicable |
- Benedikt Huttner
- Swiss National Science Foundation
- University of Geneva, Switzerland
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Days of therapy (DOT)/admission
- Days of therapy(DOT)/100 patient days
- Defined daily doses (DDD)/100 patient days (PD) and per admission
- (and 19 more...)
|
5000 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03120975 |
2017-00454
407240_167079 |
COMPASS |
September 3, 2018 |
December 31, 2019 |
March 31, 2020 |
April 19, 2017 |
February 5, 2019 |
|
- Geneva University Hospitals
Geneva, GE, Switzerland - Ente Ospedaliera Cantonale - Ospedale San Giovanni
Bellinzona, TI, Switzerland - Ente Ospedaliera Cantonale - Ospedale Civico
Lugano, TI, Switzerland
|
|
| 70 |
NCT02996656 |
Recruiting |
Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery |
- Propionibacterium Infection
|
- Drug: Cefazolin
- Drug: Ceftriaxone
|
Interventional
|
Not Applicable |
- Université de Montréal
- Tornier, Inc.
- Hopital du Sacre-Coeur de Montreal
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Skin Biopsy
- MRSA observance
- Infection
- (and 3 more...)
|
88 |
All |
18 Years and older (Adult, Older Adult) |
NCT02996656 |
PAPA |
PAPA |
December 2016 |
December 2020 |
December 2021 |
December 19, 2016 |
March 12, 2018 |
|
- Hôpital du Sacré-Cœur de Montréal
Montréal, Quebec, Canada
|
|
| 71 |
NCT02701608 |
Recruiting |
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus |
|
- Drug: Levofloxacin
- Drug: Rifampicin
- Procedure: Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
|
Interventional
|
Phase 3 |
- University Hospital, Tours
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment failure
- death from all-cause
- number of symptomatic embolic events
- (and 16 more...)
|
324 |
All |
18 Years and older (Adult, Older Adult) |
NCT02701608 |
RODEO 1 |
|
March 2016 |
October 2019 |
October 2019 |
March 8, 2016 |
September 28, 2018 |
|
- Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix
Aix en Provence, France - Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès
Alès, France - Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens
Amiens, France - (and 50 more...)
|
|
| 72 |
NCT02099240 |
Recruiting |
Patients Response to Early Switch To Oral:Osteomyelitis Study |
|
- Drug: oral antibiotics
- Procedure: intravenous antibiotics
|
Interventional
|
Early Phase 1 |
- Julio Ramirez
- University of Louisville
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Failures
- Evaluation of adverse events related to the use of antibiotics
- Cost of care from the hospital perspective
|
456 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT02099240 |
14.0185 |
PRESTO:Osteo |
April 2014 |
September 2019 |
September 2019 |
March 28, 2014 |
March 8, 2018 |
|
- University of Louisville
Louisville, Kentucky, United States
|
|
| 73 |
NCT03537495 |
Not yet recruiting |
Pharmacokinetic Study of Linezolid for TB Meningitis |
- Tuberculosis, Meningeal
- Linezolid
|
|
Interventional
|
Phase 2 |
- Universitas Padjadjaran
- Radboud University
- Global Alliance for TB Drug Development
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Linezolid exposure in blood and CSF
- Serious adverse event
- Clinical response
- (and 4 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03537495 |
TB-201805.01 |
SIMPLE |
January 2019 |
May 2019 |
July 2019 |
May 25, 2018 |
December 5, 2018 |
|
- Hasan Sadikin General Hospital
Bandung, Jawa Barat, Indonesia
|
|
| 74 |
NCT03440918 |
Recruiting |
Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit |
- Sepsis
- Procalcitonin
- Antimicrobial Stewardship
|
- Other: Procalcitonin-Guided Antimicrobial Stewardship
- Other: Baseline Antimicrobial Stewardship
|
Interventional
|
Not Applicable |
- Vanderbilt University Medical Center
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Days of antibiotic therapy in the first 14 days following randomization
- Duration of broad-spectrum antibiotic therapy
- Time from randomization to first appropriate antibiotic modification
- (and 9 more...)
|
250 |
All |
up to 17 Years (Child) |
NCT03440918 |
170778 |
ProPICU |
February 12, 2018 |
May 2019 |
May 2019 |
February 21, 2018 |
March 27, 2018 |
|
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 75 |
NCT03149640 |
Recruiting |
Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia |
- Pneumonia, Ventilator-Associated
|
- Drug: Inhaled amikacin
- Drug: Inhaled placebo
|
Interventional
|
Phase 3 |
- University Hospital, Tours
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Incidence of a first VAP episode from randomization to day 28
- Incidence of a first VAP episode in the subgroups of patients with tracheobronchial colonization or tracheobronchitis
- Incidence of VAP due to Gram negative amikacin sensitive bacteria
- (and 16 more...)
|
850 |
All |
18 Years and older (Adult, Older Adult) |
NCT03149640 |
PHRN15-SE / AMIKINHAL |
AMIKINHAL |
July 19, 2017 |
June 2020 |
June 2020 |
May 11, 2017 |
May 10, 2018 |
|
- Service de Réanimation Chirurgicale
Angers, France - Service de Réanimation Médicale - CH d'Angoulême
Angoulême, France - Service de Réanimation - CH Beauvais
Beauvais, France - (and 17 more...)
|
|
| 76 |
NCT03611257 |
Recruiting |
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases |
- Hematologic Diseases
- Bacteremia Sepsis
|
- Diagnostic Test: dRAST
- Diagnostic Test: Current standard method
|
Interventional
|
Not Applicable |
- Seoul National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients receiving optimal targeted antibiotics 72 hours after blood collection for blood culture
- Time to optimal targeted antibiotics
- Amount of broad-spectrum antibiotics use
- (and 5 more...)
|
116 |
All |
20 Years and older (Adult, Older Adult) |
NCT03611257 |
1806-173-955 |
|
September 1, 2018 |
February 2019 |
August 2019 |
August 2, 2018 |
October 1, 2018 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
|
| 77 |
NCT03016130 |
Recruiting |
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) |
- Leukemia
- Myelodysplastic Syndromes
|
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Incidence of major infections
- Incidence of infections in each diet group
- Admission frequency
- (and 8 more...)
|
568 |
All |
18 Years and older (Adult, Older Adult) |
NCT03016130 |
IRB201700581
UF-BMT-LDND-101
OCR15632 |
|
August 18, 2017 |
September 1, 2024 |
September 1, 2025 |
January 10, 2017 |
January 14, 2019 |
|
- UF Health Cancer Center
Gainesville, Florida, United States
|
|
Create an RSS feed from your search for:
Download the search results for: